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ABSTRACT
Objectives Medicinal plants are used globally as 
alternative medicines in the management of a range 
of disease conditions and are widely accepted across 
differing societies. Ethiopia hosts a large number of plant 
species (>7000 higher plant species), of which around 
12% are thought to be endemic, making it a rich source 
of plant extracts potentially useful for human health. The 
aim of this review is to evaluate Ethiopian medicinal plants 
for their anti- inflammatory, wound healing, antifungal or 
antibacterial activities.
Methods and analysis The guidance of the Preferred 
Reporting Items for Systematic Review and Meta- analysis 
Protocols (PRISMA- P) statement will be used. This review 
will consider all controlled studies of anti- inflammatory 
and wound healing properties (both in vivo and in vitro) 
and in vitro anti- infective properties of medicinal plants 
found in Ethiopia. Data sources will be EMBASE, PubMed/
Medline, Scopus and Google Scholar. Guidance documents 
on good in vitro methods and checklists for reporting in 
vitro studies will be used for quality assessment of in vitro 
studies. The risk of bias tool for animal intervention studies 
(the SYRCLE RoB tool) will be used to assess the validity 
of studies. The main outcomes will be percent inhibition 
of inflammation, time of epithelisation and tissue tensile 
strength in wounds and microbial growth inhibition.
Ethics and dissemination The findings of this systematic 
review will be disseminated by publishing in a peer- 
reviewed journal and via conference presentations. Ethical 
clearance was obtained from the Brighton and Sussex 
Medical School, Research Governance & Ethics Committee 
(RGEC) and Addis Ababa University, College of Health 
Science, Institutional Review Board.
PROSPERO registration number This systematic 
literature review has been registered with PROSPERO 
(registration number CRD42019127471).
INTRODUCTION
Herbal medicines are used worldwide as alter-
native treatments for a range of conditions 
and are widely accepted across a range of 
cultures and settings. Their medicinal values 
arise from the active substances produced by 
the plants as secondary metabolites, which 
themselves produce physiological changes in 
the human body.1 Most of the drugs currently 
used against infectious agents are derived 
from natural products or from structures 
suggested by natural product ‘leads’—chem-
ical compounds with pharmacological or 
biological activity likely to be therapeutically 
useful, but which require modification to fit 
better to the target.2
In the search for improved, safe, effec-
tive and affordable drugs for treatment of 
tropical lymphoedema, plant- derived prod-
ucts represent an attractive option.3 Herbal 
products are relatively safe, chemically 
complex mixtures composed of a range of 
constituents with multiple potential targets 
and different mechanisms of action.4 Phyto-
chemicals found in certain herbal extracts 
are reported to demonstrate analgesic and 
anti- inflammatory properties.1 Most of these 
act in a comparable manner to non- steroidal 
anti- inflammatory drugs on inflammatory 
Strengths and limitations of this study
 ► This is the first systematic review to assess 
Ethiopian medicinal plants for inflammation, wound 
healing and anti- infection properties.
 ► The review includes both in vivo and in vitro studies.
 ► Study screening and data extraction will be conduct-
ed independently by two authors.
 ► This systematic review only considers studies writ-
ten in English.
 ► It will consider a wide range of methodological ap-
proaches and uses of different types of interventions 
which may result in heterogeneous data. As a result 
of this heterogeneity, it may be impossible to con-
duct meta- analysis.
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pathways.5 Similarly, evidence suggests that medicinal 
plant products may be cost- effective promoters of wound 
healing.6
Through its geographical position, range of altitude, 
rainfall pattern and soil variability, Ethiopia has immense 
ecological diversity. Ethiopia hosts a large number of plant 
species (>7000 higher plant species), of which around 
12% are thought to be endemic, making it a rich source 
of plant extracts potentially useful for human health.7 In 
Ethiopia, traditional medicine is culturally entrenched in 
all communities, and many Ethiopian medicinal plants 
are claimed to have anti- inflammatory and wound healing 
activities.8 Phytochemical and pharmacological investiga-
tions of endemic plant extracts for the care of wounds 
and swelling caused by bacterial infections have shown 
anti- inflammatory and diuretic activities.9 10
One of the most neglected health issues within Ethiopia 
is tropical lymphoedema. Over 1.5 million Ethiopians are 
estimated to be affected by lymphoedema, predominantly 
caused by podoconiosis.11 Lymphoedema is a condition 
caused by failure of lymphatic drainage leading to accu-
mulation of protein- rich fluid in the interstitial spaces. 
Primary lymphoedema arises from genetic disorders, 
while secondary lymphoedema arises from damage to 
the lymphatic system, due to lymphatic vessel infestation, 
mineral damage, recurrent infection, lymphadenectomy 
or radiotherapy in patients with cancer.12 13
The aims of treatment of lymphoedema are to improve 
lymph drainage and reduce the incidence of ‘acute 
attacks’ (acute dermatolymphangioadenitis). Acute 
attacks are characterised by local inflammation of the skin, 
lymph nodes and lymphatic vessels resulting in very high 
fever, confusion, headache, rigours, chills and pain of the 
lymph glands.14 Although foot hygiene and skin care has 
recently been shown to be a resource- frugal approach to 
reducing frequency of acute attacks,15 few pharmacolog-
ical approaches exist. This review therefore focuses on 
preclinical studies of Ethiopian medicinal plants used to 
manage inflammation, wound and infection.
Preclinical studies include animal and in vitro studies 
which elucidate mechanisms of disease at the molecular 
level and may be used for drug screening before testing 
on humans. Many in vitro and in vivo studies have been 
conducted on the safety of Ethiopian medicinal plants 
and their efficacy against inflammation, infection and for 
wound healing. However, data from these studies have 
never been compiled. This systematic review aims to draw 
together information on Ethiopian medicinal plants used 
as anti- inflammatory, wound healing and anti- infective 
agents that might potentially be used for treatment of 
lymphoedema and associated wounds. We intend to 
answer the following questions:
 ► In in vitro and in vivo (animal) studies, do Ethiopian 
medicinal plants have anti- infective, anti- inflammatory 
or wound healing activities compared with conven-
tional treatments or placebo?
 ► Which secondary metabolites of medicinal plants 
found in Ethiopia have been investigated for 
anti- infective, anti- inflammatory or wound healing 
activities?
 ► What experimental models are most frequently used 
to investigate the efficacy of medicinal plants and 
their compounds?
In the context of this review, ‘Ethiopian medicinal 
plants’ is defined as follows:
‘Ethiopian medicinal plants’ refers to plants which are 
found in Ethiopia and have been used traditionally for 
medicinal purposes by societies in Ethiopia and elsewhere.
METHODS AND ANALYSIS
This systematic review protocol uses the guidance of 
the Preferred Reporting Items for Systematic Review 
and Meta- analysis Protocols (PRISMA- P) statement, and 
a completed PRISMA- P checklist has been included 
with this submission.16 This systematic review is regis-
tered in PROSPERO and the registration number is 
CRD42019127471.
Study design
This review considers all controlled in vivo and in vitro 
studies conducted on anti- inflammatory activity and 
wound healing, and in vitro anti- infective studies evalu-
ating the efficacy and safety of Ethiopian medicinal plants.
The components population (disease model), expo-
sure (intervention), comparator and outcome (PICO) of 
this review will be as follows:
Disease model
This includes laboratory animals (healthy mice and rats) 
used after experimentally induced inflammation and 
wound scratches; and/or cell lines used in in vitro models 
for anti- inflammatory and wound healing assays. Simi-
larly, micro- organisms (bacteria and fungi) which were 
used to assess anti- infective activity.
Intervention
This includes extracts, fractions and/or compounds from 
different parts of the plants such seeds, roots, flowers, buds 
and leaves used in the experimental (test) groups; and 
conventional drugs and placebo used in control groups. 
Medicinal plants used will be regardless of their method 
of preparations (maceration, decoctions, Soxhlet, steam 
distillation methods), but not synthesised compounds. 
There is no restriction on dosage form, concentration, 
frequency of administration (treatment), dose, duration 
of medicinal plants exposure and time of measurement 
of outcomes.
Comparator
This includes placebo, vehicle and/or conventional 
(reference) drugs used for treatment of controls. Conven-
tional (reference) drugs are known anti- inflammatory, 
wound healing or anti- infective agents which are known 
to produce results similar to those predicted by the 
hypothesis. They are used as a benchmark against which 
to predict the efficacy and safety of plant substances. 
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Vehicles are not expected to produce an effect but help 
to identify outside influences on the experiment, such as 
contamination. Similarly, for placebo (non- intervention) 
controls, groups will not receive a treatment or given an 
inert substance.
Outcomes
The primary outcomes that will be analysed in this review 
will be as follows:
For in vivo anti- inflammatory studies, linear paw 
circumference using a plethysmometer or water displace-
ment method to measure the volume of oedematous legs.
For in vitro studies, percent inhibition of cyclo- 
oxygenase enzyme production, inflammatory biomarkers 
such as vascular cell adhesion molecule-1, interferon 
gamma (IFN-γ)- induced protein 10, monokine- induced 
by interferon, nitric oxide (NO) production, interleu-
kin-1β (IL-1β) and IL-6 mRNA expressions, quantity of 
proinflammatory cytokines (tumour necrosis factor-α 
(TNF-α) and IL-6), median inhibitory concentration 
(IC50) values, percentage inhibition of denatured protein 
and gene expression of inflammatory cells using molec-
ular techniques such as ELISA and western blot, and NO 
assay by measuring optical density, and measuring the 
amount of gene expressed.
For in vivo wound healing, wound contraction (area of 
wound), percent tensile wound strength (skin breaking 
strength) using water flow method, period of epithelisa-
tion (the number of days required for falling off the dead 
tissue), collagen formation, fibroblast proliferation and 
angiogenesis evaluated microscopically.
For in vitro wound healing studies, cell proliferation 
and migration rates measured using UV spectrophotom-
eter and calculated as percent cell viability, and IC50 for 
free radical scavenging activity of medicinal plants.
For the anti- infective studies, diameter (mm) of the 
zone of inhibition of bacterial growth measured at each 
test level for agar well and paper disc diffusion assay. For 
the microdilution methods, minimum inhibitory concen-
tration (MIC) and minimum bactericidal concentration 
(MBC) visually identified as colour changes (colorimetric 
methods), or clear or turbid solutions (non- colorimetric 
methods).
Eligibility criteria
Inclusion criteria:
 ► Published works including theses, articles and 
proceedings, which deal with efficacy evaluation 
of antibacterial, antifungal, anti- inflammatory and 
wound healing activities in in vivo and in vitro studies.
Exclusion criteria:
 ► Newspaper articles.
 ► Unpublished work.
 ► Reviews.
Information sources
We will conduct searches in electronic databases using 
a combination of free text keywords and Medical 
Subject Heading (MeSH) terms. EMBASE, PUBMED/
MEDLINE, Scopus of Science and Google Scholar will be 
used as sources of information for the search. Grey liter-
ature such as theses and dissertations, technical reports, 
working papers, evaluation reports, conference proceed-
ings, patents and preprints will be included in the review.
Search strategy
The search will include all articles containing the descrip-
tors published up to 30 August 2019 for all databases. 
There will be restriction of language to English for the 
identified articles in all databases. The search strategy 
will include all articles containing the descriptors. Struc-
tured search strategies will be developed using the vocab-
ulary terms of each database and targeting the ‘title’ and 
‘abstract’ fields. We will also search manually using the 
references of previously published works. The following 
search terms will be used: Ethiopia, medicinal plants, 
Ethiopian medicinal plants, herbal products, care, 
management, therapeutic, lymphoedema, lymphedema, 
swelling, podoconiosis, elephantiasis, wound, wound 
healing, inflammation, anti- inflammatory, bacteria, anti-
bacterial, fungi, anti- infective, antimicrobial, anti- fungal 
and other related words or phrases. A PUBMED search is 
included in online supplementary annex 1.
Selection of studies
After electronic searching, the records will be uploaded to 
Mendeley. Assessors will pilot some studies before under-
taking full study selection. All studies will be screened 
independently by two investigators (DN and BL) by scan-
ning the titles and abstracts of the articles based on the 
inclusion criteria. For the documents that fit the inclu-
sion criteria, the investigators will read the entire article 
to confirm if it meets the criteria and prepare to extract 
relevant information. Disagreements will be resolved by 
discussion between the two investigators and if disagree-
ment persists, we will discuss with a third party (GD).
Data extraction
Two reviewers (DN and BL) will independently extract 
data using a data extraction form and summarise exper-
imental works including study types. The Cochrane data 
collection form for interventional reviews will be custom-
ised to our situation and used for data extraction. A cali-
bration exercise will be done before starting the review 
to ensure consistency across the reviewers. Reviewers will 
resolve disagreements with the help of the third investi-
gator (GD or EM). Authors will be contacted if informa-
tion is unclear. The following data will be extracted from 
the respective study models.
For the animal studies: title of the study, name of the 
first author, year of publication, type of study, country 
where study conducted, species/(sub/strain) of labora-
tory animals, number of groups and number of animals 
per group, types of diet used for laboratory animals, 
housing condition of laboratory animals, scientific name 
of the medicinal plant(s), vernacular name of medicinal 
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plants, family of the medicinal plants, voucher number, 
whether plants identified by a botanist/herbalist, plant 
parts used/extracted, types of extracts/fractions/
compounds used, positive controls used, assay methods 
(model) used, dose regimen (dose level or concentration 
of plant material used per group and frequency), route 
of administration, duration of the exposure of animals to 
treatment, time of measurement/observation period of 
outcomes, endpoints measured, statistical method used, 
dose or concentration (eg, mean, median, frequency, 
measures of precision or variance) used, statistical signifi-
cance of dose levels, author’s interpretation and outcome 
measured at a population level or individual level.
For the in vitro studies: title of the study, name of the 
first author, year of publication, health outcome category, 
potential conflict of interest, country where the study 
conducted, type of study, name of the assay, study design, 
aim of the study, name and sources of cell lines/kits, name 
and source of media used, disease model, scientific name 
of the plant(s)/compounds, vernacular name, family 
of the plants, plant authenticated/identified, voucher 
number, plant parts used/extracted, extraction method 
used, types of plant extracts/fractions/compounds, nega-
tive control used, positive controls used, concentration 
regimen (dose level or concentration of plant material 
used per group and frequency), duration of the exposure, 
number of test groups/number of cell line per group, how 
many experimental duplicates were conducted, time of 
measurement/observation period, endpoints measured, 
methods to measure endpoint, are study designs clearly 
stated, statistical method used, results per dose or concen-
tration (eg, mean, median, frequency, measures of preci-
sion or variance), statistical significance of other dose 
levels, author's interpretation, outcome measured at a 
population level or individual level and whether outcome 
measures meet the criteria for inclusion.
When individual studies have multiple treatment 
groups, we will combine the groups from multiple arms 
into one group to avoid the possibility of introducing 
bias caused by multiple statistical comparisons with one 
control group.16
Outcome measured
For the in vivo studies of anti- inflammatory activity, 
the primary outcomes will be percent inhibition of the 
carrageenan- induced oedema and/or the percent inhibi-
tion of the weight of granuloma tissue formation relative 
to the controls. In in vitro anti- inflammatory studies, the 
primary outcomes will be percent inhibition of inflam-
matory cells and proinflammatory cells which includes 
percent inhibition of lipoxygenase enzymes, percent 
inhibition of protein denaturation, levels of inflammatory 
cytokines (TNF-α, IL-6, IL-10 and IFN-γ), level of cyclo- 
oxygenase and concentration of NO in inflammation- 
induced cell lines after treatment by plant extracts. The 
type of data (variables) that will be extracted for anti- 
inflammatory activity, wound healing and anti- infective 
activity are continuous (percentage and µg/mL, mg/
mL).
In in vivo wound healing assays, the primary outcomes 
will be percentage wound contraction, period of epithe-
lisation and percent of wound tensile strength in experi-
mentally induced wounds in laboratory animals, whereas 
for the in vitro wound healing assays, relative cell 
spreading and migration, percent cell proliferation and 
viability, and free radical scavenging activity of medicinal 
plants will be the primary outcomes. In in vitro studies 
of anti- infective activity, percent inhibition of growth of 
micro- organisms, MIC and concentration that inhibits 
50% of the growth of micro- organisms (IC50) will be the 
primary outcomes. Secondary outcomes will be long- term 
toxicity, death of animals and experiment dropouts.
Assessment of risk of bias
Two review authors (DN and BL) will independently 
assess the risk of bias for each study included. Disagree-
ments will be resolved by consensus or by consulting a 
third party (GD or EM). The critical appraisal process 
for in vivo anti- inflammatory activity and wound healing 
will be performed using the Risk of Bias tool for animal 
intervention studies (SYRCLE’s RoB tool)17 and Animal 
Research: Reporting of In vivo Experiments (ARRIVE) 
guidelines to assess the internal validity of the studies.18 
These tools will be used to assess the methodological 
quality of studies to generate reliable information and 
create transparency. Studies with highly unacceptable 
levels of bias will be excluded. A highly unacceptable 
level of bias occurs when studies have serious errors in 
conducting, analysis or reporting, have large amounts 
of missing information or discrepancies in reporting. 
For instance, in randomisation of experimental animals, 
if there is direct evidence that animals were allocated 
to study groups using a non- random method, the study 
would be categorised as ‘definitely high risk of bias’. The 
judgement of bias will be categorised as yes, no or unclear. 
A ‘yes’ judgement indicates a low risk of bias; a ‘no’ judge-
ment indicates high risk of bias; the judgement will be 
‘unclear’ if insufficient details are reported to assess the 
risk of bias properly. Studies will be evaluated for their 
internal and external validity. Reviewers will judge the risk 
of bias for individual elements from five domains of bias 
(selection, performance, attrition, reporting and other) 
using the SYRCLE’s risk of bias tool for animal studies—
Appendix D—and decide the inclusion and exclusion of 
the studies.17
The following criteria will be used to assess the quality 
of individual in vivo studies:
 ► Systematic differences between study groups at the 
start of an experiment (selection bias).
 – Did the investigators describe a random com-
ponent in the sequence generation process (eg, 
methods used for randomisation of the animals)?
 – Balanced distribution of relevant baseline charac-
teristics for the intervention and control groups 
(eg, age, sex, weight of the animals).
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 – If relevant, did the investigators adequately adjust 
for unequal distribution of some relevant baseline 
characteristics in the analysis?
 ► Systematic differences occur in how the groups are 
handled during a study (performance bias).
 – Adequacy of timing of disease induction in both 
the test and the control groups.
 – Experimental animals random housing to test and 
control group, and feeding conditions.
 – Was the allocation to the different groups adequate-
ly concealed during the study such as blinding of 
the caregivers and/or investigators from knowing 
which intervention each animal received during 
the experiment (labelling the cages and drug con-
tainers with code)?
 ► Circumstances during the experiment in both experi-
mental and control groups.
 – Timing of administration of the placebo and ex-
perimental extracts.
 – Instruments used to conduct experiment differ be-
tween experimental and control groups.
 ► Systematic differences occur between groups in how 
outcomes are ascertained, diagnosed or verified 
(detection bias).
 – Was the outcome assessor blinded? If not blinded, 
do review authors judge that the outcome is not 
likely to be influenced by lack of blinding?
 – Did the investigators randomly pick an animal 
during outcome assessment, or did they use a ran-
dom component in the sequence generation for 
outcome assessment?
 ► Whether all animals receiving the same intervention 
are caged together, but analysis was conducted as if 
every single animal was one experimental unit.
 ► Incomplete data (attrition bias).
 – Were all animals included in the analysis?
 – Are missing outcome data imputed using appropri-
ate methods?
 – Are missing outcome data balanced in numbers 
across intervention groups, with similar reasons for 
missing data across groups?
 ► Selective reporting (reporting bias).
 – Was the study protocol available and were all of the 
study’s prespecified primary and secondary out-
comes reported in the current manuscript?
 – Was the study protocol not available, but was it 
clear that the published report included all ex-
pected outcomes (ie, comparing the Methods and 
Results sections).
 ► Other biases—unit of analysis errors, inappropriate 
influence of funders and adding new laboratory 
animals to replace dropouts from the original popu-
lation and so on.
The critical appraisal process for in vitro anti- 
inflammatory activity and wound healing will be 
performed using the Guidance Document on Good In 
vitro Method Practices (GIVIMP)19 and the Checklist for 
Reporting In vitro Studies guidelines.20 For the in vitro 
antibacterial studies, checklists for good practice for 
pharmaceutical microbiology laboratories (WHO) will 
be customised and used for quality assessment.21 22 The 
following key criteria will be used to assess the quality of 
individual in vitro studies:
 ► Assurance of the quality of all materials and methods, 
and of their use and application, in order to maintain 
the integrity, validity and reproducibility of the labora-
tory work conducted.
 – Test definition (including purpose, need and sci-
entific basis).
 – Laboratory reproducibility, validity and interna-
tional acceptance of the in vitro method(s).
 – Clearly written and well- documented in vitro meth-
od description, and related standard operating 
procedure (SOP).
 – Did the in vitro method(s) include all relevant and 
reliable positive and negative controls, including 
acceptance criteria?
 – SOP/guidelines cell culture maintenance, and 
safety practices for use and disposal of the test sys-
tem, including transport and containments.
 – Relevant documentation of proof of sterility, date 
of arrival, expiry dates and batch numbers (as the 
suitability and acceptability) of laboratory consum-
ables (materials).
 – Evidence of provision of relevant and adequate ed-
ucation and training for all personnel, to promote 
high quality work and safety.
 ► Are the in vitro cell and tissue culture facilities fit for 
purpose? Evidence of quality laboratory management 
maintained:
 – Was the facility designed or adapted to minimise 
the risk of errors (eg, mix- ups) and to avoid (cross- 
contamination) which may adversely affect the 
quality of the work performed?
 – Is appropriate environment maintained for the 
type of work conducted in the laboratory (appro-
priate biosafety level)?
 – Is there an appropriate documented procedure for 
disinfection of work surfaces, safety cabinets and 
equipment?
 – Any establishment and maintenance of adequate 
measures to protect individuals and the environ-
ment from any potential hazards.
 ► Is equipment regularly maintained, monitored and 
calibrated?
 ► Compliance of laboratory suppliers with good labora-
tory practice principles, such that test system providers 
should adhere to a formal quality system, such as 
International Standards (Good Manufacturing Prac-
tice, Good Laboratory Practices, International Organ-
ization for Standards).
 ► Evidence that the cell lines are free from any contam-
inants, indicate functionality, genetic stability and 
identity; reference data to assess the relevance of 
in vitro methods; does the media and serum used 
precisely specified (source, batch number, expiry 
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date, components) and meet the required specifica-
tions; does the maximum acceptable levels of serum 
components, such as immunoglobulins and haemo-
globin are defined well.
 ► Are reference and control items described well, such 
as negative and positive controls? Suitability of refer-
ence and control items and justification for the selec-
tion of the reference item(s), stability and solubility of 
the reference and control items.
 ► Are applicability domain of the in vitro method 
described well, as well as any limitations or exceptions?
 ► Is concentration of solvent(s) used without interfering 
with the in vitro method? Compatibility and toxicity of 
the solvent with the test system assessed, to select the 
appropriate solvent at an acceptable final concentra-
tion in the in vitro method medium.
 ► Is the number of replicates for each testing condition, 
including concentration level(s) used for the refer-
ence and control item(s), and test items and so on, 
specified?
 ► Is there evidence that cell seeding, treatment and 
measurement is performed in a uniform fashion 
across the whole plate (well- to- well), between plates 
and across multiple runs (minimise any potential 
systematic effects).
 ► Statistical method used for data analysis and 
interpretation.
Then, risk of bias criteria will be judged as ‘low’, ‘high’ 
or ‘unclear’. We plan to report only studies in which risk 
of bias is low or moderate and to omit high risk of bias 
studies from analysis.
Data synthesis
All included studies will be classified for data synthesis 
into six different models according to the type and 
purpose of the studies. These are in vivo and in vitro anti- 
inflammatory studies, in vivo and in vitro wound healing 
studies, antibacterial and anti- fungal activity studies. For 
the narrative synthesis, methods and techniques such 
as textual description of studies, groupings, tabulation, 
thematic and content analysis for translating data will 
be used. Then, a narrative (qualitative) synthesis which 
describes the characteristics of studies and compares 
the effect of each plant extract relative to control, main 
parameters measured/analysed, quality of included 
studies and the risk of bias of all studies will be described 
and data will be presented in a table.
Assessment of heterogeneity
We will evaluate heterogeneity descriptively from the 
narrative synthesised data, and potential reasons for 
heterogeneity will be found by examining individual 
study and subgroup characteristics. From the qualitative 
review, similarity in intervention, methodology and statis-
tical methods used among the studies will be considered 
good evidence for homogeneity. In the case of interven-
tional, methodological or statistical heterogeneity, study 
results will not be reported as a pooled effect estimate 
in meta- analysis. In addition, if meta- analysis is possible, 
statistical heterogeneity will be also tested using the χ2 
test (significance level: 0.1) and the I2 statistic. If statis-
tical heterogeneity is observed (I2>=50% or p<0.1), the 
random effects model will be used.
The Mantel- Haenszel method will be used for the fixed 
effect model if tests of heterogeneity are not significant. 
If heterogeneity is substantial, we will not perform a meta- 
analysis; a narrative, qualitative summary will be done. 
If there is no good evidence for homogeneous effects 
across studies of low risk bias, data will be summarised by 
means of a random- effects model23; and random- effects 
meta- analyses will be interpreted with consideration of 
the whole distribution effects by presenting a prediction 
interval.23 Statistical analysis will be performed according 
to statistical guidelines of the Cochrane Handbook for System-
atic Reviews of Interventions.24
Measurement of treatment effect
Data will be analysed by weighted mean differences with 
95% CI or standardised mean differences if different 
measurement scales are used. Skewed data and non- 
quantitative data will be presented descriptively.
Unit of analysis
The primary analysis will include individually randomised 
studies. All included studies will be assessed to deter-
mine the unit of randomisation and whether this unit 
of randomisation is consistent with the unit of analysis. 
For cluster randomised trials, interclass correlation coef-
ficients will be extracted to modify the results using the 
methods described in The Cochrane Handbook for System-
atic Reviews of Interventions. In studies of more than two 
treatment groups, additional treatment arms will be 
presented. Where the additional treatment arms are not 
relevant, they will not be considered. In this systematic 
review outcomes will be measured with percent and µg/
mL, mg/mL.
Dealing with missing data
If there are missing data, the original author of the study 
will be contacted. If missing data cannot be obtained or 
if SD for outcomes are not complete, these values will be 
imputed by assuming the SD of the missing outcome to 
be the average of the SD from those studies where this 
information was reported; and impact of imputation on 
meta- analyses will be assessed by means of sensitivity anal-
ysis.
Sensitivity analysis
To determine publication bias, we will examine whether 
the protocol was published before the animal or in vitro 
study was executed. The potential for reporting bias will 
be further explored by funnel plot and Egger’s regression 
test for 10 and more studies. An asymmetrical funnel plot 
or a p value of <0.10 on Egger’s test will be considered 
to indicate the presence of publication bias. For very 
small sample size, the pooled SD will be measured in the 
formula for precision (1/variance) in Egger regression. 
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Selective reporting of outcomes will be also evaluated 
(outcome reporting bias). Small sample bias will also be 
assessed by comparing fixed estimated effect with the 
random- effects model. An option of comparing outcomes 
reported in the Methods and Results sections will be used 
when a protocol is not available.
Assessing certainty of evidence included in the review
Grading of the systematic review will be done using the 
guidelines of the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) system 
which has been adapted for preclinical animal interven-
tional studies. Quality of evidence will be categorised as 
high, moderate, low or very low quality.25
DISCUSSION
Systematic reviews provide the highest quality evidence 
on effectiveness of a treatment or service. By conducting 
this review, we will generate evidence for potential inter-
vention compounds derived from Ethiopian medicinal 
plants that may be of value to explore more thoroughly 
for treatment of tropical lymphoedema.
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